Congratulations to ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) on its successful listing

ImmuneOnco was established in June 2015 in Zhangjiang High tech Science and Technology Park, China (Shanghai) Pilot Free Trade Zone, which is a clinical biotechnology company dedicated to developing innovative tumor immunotherapy. As one of the few biotechnology companies in the world that can systematically utilize innate and adaptive immunity, Yiming Angke stands out in the industry. Currently, approved immunotherapies mainly focus on the adaptive immune system, and often face limited clinical benefits due to low response rates and inevitable drug resistance or recurrence in many cancer indications. By using both innate and adaptive immune systems, we can overcome the limitations of current T cell based immunotherapy and address the significant unmet medical needs of cancer patients.

 

With regard to this listing application, AVISTA Group is honoured to be engaged in providing valuation services in relation to preferred shares, employee stock option and restricted stock unit for financial reporting purposes.

 

Congratulations again to ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) on its successful listing. The issue price is HKD18.6 per share, and the amount of funds raised is HKD319 million.